The goal of the University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC Lymphoma SPORE) Career Development Program (CDP) is to develop knowledgeable, well-trained scientists experienced in multidisciplinary research for future studies in translational lymphoma research. The provision of ample opportunities for training and career enhancement is a top priority of the University of Iowa and Mayo Clinic scientific communities. The extensive research and training base available at these two institutions provides strong support for the UI/MC Lymphoma SPORE CDP. The primary objectives of the CDP are to: (1) train young investigators (senior postdoctoral fellows and young faculty) in translational, multidisciplinary clinical or basic lymphoma research;(2) redirect established investigators to further lymphoma research;and (3) collaborate with investigators from other institutions who are interested in pursuing a research career in translational lymphoma research. During the initial funding period 6 young investigators received awards. Their work has led to the discovery of novel translocations, potential new methods of antigen presentation, and new treatments that are now being tested in clinical trials. During the next funding period, the UI/MC Lymphoma SPORE will maintain: (1) a stringent candidate selection system;(2) comprehensive trainee guidance by a mentor and other investigators from both sites;(3) support through a scientific mentor group (the Individual Trainee Advisory Committee) comprised of investigators from both sites with expertise in each trainee's area of interest;(4) multi-disciplinary research courses and on-going training activities such as the Multidisciplinary Cancer Seminar Series and Lymphoma Group meetings at both sites;(5) encouragement of collaboration with Investigator Group meetings at both sites;(6) encouragement of collaboration with investigators at both Iowa and Mayo and (7) opportunities for research enhancement through the Developmental Research Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-08
Application #
7878115
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
8
Fiscal Year
2009
Total Cost
$93,469
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Naik, Shruthi; Galyon, Gina D; Jenks, Nathan J et al. (2018) Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. Mol Cancer Ther 17:316-326
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73
Saad Aldin, Ehab; McNeely, Parren; Menda, Yusuf (2018) Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. Clin Nucl Med 43:195-198
Link, Brian K; Day, Bann-Mo; Zhou, Xiaolei et al. (2018) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol :
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Holahan, Heather M; Farah, Ronda S; Fitz, Sara et al. (2018) Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 57:1314-1319
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561

Showing the most recent 10 out of 387 publications